


Tavaborole

Cat. No.:	HY-10980		
CAS No.:	174671-46-6		
Molecular Formula:	C ₇ H ₆ BFO ₂		
Molecular Weight:	151.93		
Target:	Fungal; Antibiotic		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (658.20 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	6.5820 mL	32.9099 mL	65.8198 mL
	5 mM	1.3164 mL	6.5820 mL	13.1640 mL
	10 mM	0.6582 mL	3.2910 mL	6.5820 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (16.45 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (16.45 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (16.45 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	Tavaborole (AN-2690) is an antifungal agent with activity against Trichophyton species, in a topical solution formulation for the potential treatment of onychomycosis.
In Vitro	<p>Tavaborole (AN-2690) shows an 8-fold increase in activity against <i>C. neoformans</i>, and an 8-fold increase in activity against <i>A. fumigatus</i>^[1]. Tavaborole (AN-2690) obviously inhibit the cells expressing GILeuRS-D444A, but has no effect on the cells expressing GILeuRS and GILeuRS-D444E^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- AMB Express. 2022 Dec 1;12(1):151.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Baker SJ, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006 Jul 27;49(15):4447-50.

[2]. Zhou XL, et al. Post-transfer editing by a eukaryotic leucyl-tRNA synthetase resistant to the broad-spectrum drug AN2690. Biochem J. 2010 Sep 1;430(2):325-33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA